| 296.52 Delayed Data As of Jul 22 |  -1.59 / -0.53%Today’s Change | 287.66 Today|||52-Week Range 442.00 | -20.61% Year-to-Date |
| Previous close | 298.11 |
| Today’s open | 298.20 |
| Day’s range | 294.70 - 300.32 |
| Volume | 608,965 |
| Average volume (3 months) | 841,456 |
| Market cap | $32.2B |
| Earnings growth (last year) | +100.98% |
| Earnings growth (this year) | -5.36% |
| Earnings growth (next 5 years) | +9.00% |
| Revenue growth (last year) | +14.28% |
| P/E ratio | 14.0 |
| Price/Sales | 6.39 |
| Price/Book | 3.72 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALXNAlexion Pharmaceutic... | +1.52 | +1.26% |
| VRTXVertex Pharmaceutica... | -0.05 | -0.03% |
| INCYIncyte Corp | +1.17 | +1.45% |
| SGENSeattle Genetics Inc | +1.00 | +1.33% |
| Next reporting date | August 6, 2019 |
| EPS forecast (this quarter) | $5.32 |
| Annual revenue (last year) | $6.7B |
| Annual profit (last year) | $2.4B |
| Net profit margin | 36.42% |
Sector Health Technology |
Industry Biotechnology |
Co-President, Chief Executive Officer & Director Leonard S. Schleifer |
Co-President, Director & Chief Scientific Officer George Damis Yancopoulos |
Corporate headquarters Tarrytown, New York |
